Please ensure Javascript is enabled for purposes of website accessibility
Value Investor
Wealth Building Opportunites for the Active Value Investor

July 20, 2022

Other than Citigroup’s earnings release and Barrick Gold’s release of preliminary sales data, no other company produced meaningful news. Perhaps this is to be expected when investors are putting immense weight on company-specific results and their respective outlooks.

Quiet Week as We Wait For Our Companies To Report
Other than Citigroup’s earnings release and Barrick Gold’s release of preliminary sales data, no other company produced meaningful news. Perhaps this is to be expected when investors are putting immense weight on company-specific results and their respective outlooks.

Citi’s results were much stronger than anticipated. This, along with the company maintaining its full-year revenue and expense guidance, led to a jump in the shares. These results run counter to the narrative that banks are in a very difficult environment, as the flatter yield curve is supposed to crimp lending profits, the slowing economy is supposed to weaken its credit position and the difficult capital markets are supposed to slash deal revenues. Citi is showing that there is more to the bank than the narrative suggests. As bottom-up investors, we find that this is true for many companies much of the time.

For now, there isn’t much else to say. The market continues to show considerable volatility in both directions, the economic outlook seems to change with the rising and setting of the sun, China remains unpredictable as it ramps up its geopolitical rhetoric while its economy continues to wobble, and the surge in inflation suggests that the future remains unpredictable. These are only a few of the ongoing crosscurrents: there are too many that are moving too quickly to effectively weigh them.

So, we’ll wait for more of our companies to report their solid, fact-based, on-the-ground results.

Share prices in the table reflect Tuesday (July 19) closing prices. Please note that prices in the discussion below are based on mid-day July 19 prices.

Note to new subscribers: You can find additional color on our thesis, recent earnings reports and other news on recommended companies in prior editions of the Cabot Undervalued Stocks Advisor, particularly the monthly edition, on the Cabot website.

Send questions and comments to

Today’s Portfolio Changes

Last Week’s Portfolio Changes

Upcoming earnings reports
Thursday, July 21: Dow (DOW)
Tuesday, July 26: The Coca-Cola Company (KO)
Tuesday, July 26: Sensata Technologies (ST)
Thursday, July 28: Merck (MRK)
Friday, July 29: Allison Transmission Holdings (ALSN)
Friday, July 29: MolsonCoors Beverage Company (TAP)

Growth/Income Portfolio
Cisco Systems (CSCO) is facing revenue pressure as customers migrate to the cloud and thus need less of Cisco’s equipment and one-stop-shop services. Cisco’s prospects are starting to improve under a relatively new CEO, who is shifting Cisco toward a software and subscription model and is rolling out new products, helped by its strong reputation and entrenched position within its customers’ infrastructure. The company is highly profitable, generates vast cash flow (which it returns to shareholders through dividends and buybacks) and has a very strong balance sheet.

While Cisco shares’ roundtrip from our initial recommendation at 41.32 to 64 and back to 41 or so is frustrating, this is not the time to sell the stock. The fundamentals remain reasonably stable and likely to tick back upward, and profits seem likely to improve, as well. The shares will likely come back to life as earnings reports show favorable growth and profit trends, so investors will need some patience. If we have a recession in global tech spending, Cisco would likely feel the downturn but not as severely as other technology companies due to the mission-critical nature of its products and services.

There was no significant company-specific news in the past week.

The valuation is attractive at 8.6x EV/EBITDA and 13.0x earnings, the shares pay a sustainable 3.5% dividend yield, the balance sheet is very strong and Cisco holds a key role in the basic plumbing of technology systems even if its growth rate is only modest.

CSCO shares rose 2% in the past week and have 51% upside to our 66 price target. BUY

The Coca-Cola Company (KO) is best known for its iconic soft drinks yet nearly 40% of its revenues come from non-soda beverages across the non-alcoholic spectrum. Its global distribution system reaches nearly every human on the planet. Coca-Cola’s longer-term picture looks bright but the shares remain undervalued due to concerns over the pandemic, the secular trend away from sugary sodas, and a tax dispute which could cost as much as $12 billion (likely worst-case scenario). The relatively new CEO James Quincey (2017) is reinvigorating the company by narrowing its over-sized brand portfolio, boosting its innovation and improving its efficiency, as well as improving its health and environmental image. Coca-Cola’s balance sheet is sturdy, and its growth investing, debt service and dividend are well-covered by free cash flow.

There was no significant company-specific news in the past week.

KO shares slipped 1% in the past week and have 11% upside to our 69 price target. Coca-Cola’s fundamentals remain sturdy with respectable revenue, profit and free cash flow growth. Management continues to focus on execution in its core business while generally avoiding any major non-core commitments. HOLD

Dow Inc. (DOW) merged with DuPont to create DowDuPont, then split into three companies in 2019 based on product type. The new Dow is the world’s largest producer of ethylene/polyethylene, the most widely used plastics. Investors undervalue Dow’s hefty cash flows and sturdy balance sheet largely due to its uninspiring secular growth traits, its cyclicality and concern that management will squander its resources. The shares are driven by: 1) commodity plastics prices, which are often correlated with oil prices and global growth, along with competitors’ production volumes; 2) volume sold, largely driven by global economic conditions, and 3) ongoing efficiency improvements (a never-ending quest of all commodity companies). We see Dow as having more years of strong profits before capacity increases signal a cyclical peak, and expect the company to continue its strong dividend, reduce its pension and debt obligations, repurchase shares slowly and restrain its capital spending.

Industry conditions are healthy but investor worries about a global recession are pressuring Dow’s shares. The primary concern: slowing demand could weigh on pricing – which is the primary driver of Dow’s exceptionally strong earnings. Tight supplies and high energy inputs have driven up the prices that Dow’s products command, but as demand weakens, pricing could slip. Fortunately, global prices are being propped up by Europe’s very high local natural gas prices (due to falling imports from Russia).

Dow’s volumes would decline, but this is a lesser concern as volumes tend to change moderately even in slowdowns. And Dow’s volumes are supported by its status as one of the world’s lowest-cost producers, helped by relatively cheap domestic natural gas prices.

Dow took great advantage of its recent high-profit period to improve its balance sheet and upgrade its operations. Even in a slowdown, we see the company sustaining its dividends, backed by what will likely be still-sizeable free cash flow.

There was no significant company-specific news in the past week.

Dow shares rose 4% in the past week as investors seem to be worrying less about the U.S. and global economy. Higher oil prices helped the shares, as well. Estimates for 2022 and 2023 earnings ticked fractionally lower again this past week. We will get considerably more color on the post-earnings conference call.

The shares have 49% upside to our 78 price target and offer an attractive 5.3% dividend yield. BUY

Merck (MRK) shares are undervalued as investors worry about Keytruda, a blockbuster oncology treatment (about 30% of revenues) which faces generic competition in late 2028. Also, its Januvia diabetes treatment may see generic competition next year, and like all pharmaceuticals it is at-risk from possible government price controls. Yet, Keytruda is an impressive franchise that is growing at a 20% rate and will produce solid cash flow for nearly seven more years, providing the company with considerable time to replace the potential revenue loss. Merck’s new CEO, previously the CFO, is accelerating Merck’s acquisition program, which adds return potential and risks to the story. The company is highly profitable and has a solid balance sheet. It spun-off its Organon business in June 2021 and we think it will divest its animal health segment sometime in the next five years.

There was no significant company-specific news in the past week.

Merck shares slipped 1% in the past week and have about 7% upside to our 99 price target. The company has a strong commitment to its dividend (3.0% yield) which it backs up with generous free cash flow, although its shift to a more acquisition-driven strategy will slow the pace of dividend increases. While the shares have pulled back, we are retaining our Hold rating as rising interest rates reduce the upside potential value of its shares. HOLD

Buy Low Opportunities Portfolio
Allison Transmission Holdings, Inc. (ALSN) – Allison Transmission is a midcap ($6.4 billion market cap) manufacturer of vehicle transmissions. Many investors view this company as a low-margin producer of car and light truck transmissions that is destined for obscurity in an electric vehicle world. However, Allison produces no car and light truck transmissions, instead it focuses on the school bus and Class 6-8 heavy-duty truck categories, where it holds an 80% market share. Its 35% EBITDA margin is sharply higher than its competitors and on-par with many specialty manufacturers. And, it is a leading producer and innovator in electric axles which all electric trucks will require. Another indicator of its advanced capabilities: Allison was selected to help design the U.S. Army’s next-generation electric-powered vehicle. The company generates considerable free cash flow and has a low-debt balance sheet. Its capable leadership team keeps its shareholders in mind, as the company has reduced its share count by 38% in the past five years.

There was no significant company-specific news in the past week.

Allison shares rose 2% in the past week and have 24% upside to our 48 price target. The stock pays an attractive and sustainable 2.2% dividend yield to help compensate for the wait. BUY

Arcos Dorados (ARCO), which is Spanish for “golden arches,” is the world’s largest independent McDonald’s franchisee. Based in stable Uruguay and listed on the NYSE, the company produces about 72% of its revenues in Brazil, Mexico, Argentina and Chile. The shares are depressed as investors worry about the pandemic, as well as political/social unrest, inflation and currency devaluations. However, the company has a solid brand and high recurring demand and is well positioned to benefit as local economies re-open. The leadership looks highly capable, led by the founder/chairman who owns a 38% stake, and has the experience to successfully navigate the complex local conditions. Debt is reasonable relative to post-recovery earnings, and the company is currently producing positive free cash flow.

Macro issues, including issues in Brazil related to its economic conditions (in particular, inflation, running at an 11.3% rate), currency and the chances that a socialist might win this year’s Brazilian presidential elections, will continue to move ARCO shares.

There was no significant company-specific news in the past week.

Earnings estimates jumped about 6%, reflecting more analyst optimism about the company’s outlook. ARCO shares rose 6% in the past week and have 27% upside to our 8.50 price target. BUY

Aviva, plc (AVVIY), based in London, is a major European company specializing in life insurance, savings and investment management products. Amanda Blanc was hired as the new CEO in July 2020 to revitalize Aviva’s laggard prospects. She divested operations around the world to re-focus the company on its core geographic markets (U.K., Ireland, Canada), and is improving Aviva’s product competitiveness, rebuilding its financial strength and trimming its bloated costs. Aviva’s dividend has been reduced to a more predictable and sustainable level with a modest upward trajectory. Excess cash balances are being directed toward debt reduction and potentially sizeable special dividends and share repurchases.

Much of our interest in Aviva is based on its plans for returning its excess capital to shareholders, including share repurchases and dividends. These distributions could be substantial. We also look for incremental shareholder-friendly pressure from highly regarded European activist investor Cevian Capital, which holds a 5.2% stake.

There was no significant company-specific news in the past week. Please note that the ticker symbol for the ADS has reverted back to “AVVIY” following their overly-complicated share buyback transaction.

Aviva shares fell 1% in the past week and have about 48% upside to our 14 price target. Based on management’s estimated dividend for 2023 (which we believe is highly credible), the shares produce a generous 8.8% yield. Based on this year’s actual dividend, the shares offer an attractive 5.9% dividend yield. BUY

Barrick Gold (GOLD), based in Toronto, is one of the world’s largest and highest quality gold mining companies. About 50% of its production comes from North America, with the balance from Africa/Middle East (32%) and Latin America/Asia Pacific (18%). Barrick will continue to improve its operating performance (led by its new and highly capable CEO), generate strong free cash flow at current gold prices, and return much of that free cash flow to investors while making minor but sensible acquisitions. Also, Barrick shares offer optionality – if the unusual economic and fiscal conditions drive up the price of gold, Barrick’s shares will rise with it. Given their attractive valuation, the shares don’t need this second (optionality) point to work – it offers extra upside. Barrick’s balance sheet has nearly zero debt net of cash. Major risks include the possibility of a decline in gold prices, production problems at its mines, a major acquisition and/or an expropriation of one or more of its mines.

Barrick reported preliminary second-quarter unit volumes. Full results will be reported on August 8. In the preliminary report, the company said it produced 1.04 million ounces of gold and 120 million pounds of copper. It also said that it remains on track to meet its full-year gold and copper guidance. For long-term investors, the company’s ability to set healthy guidance numbers and then meet/exceed them is critical, as it indicates a predictable and controllable operating process and generally high quality mines.

Over the past week, commodity gold fell 1% to $1,713/ounce, leaving gold down 6% year to date. The 10-year Treasury yield rose to 3.0% as investors worried incrementally more about a recession.

The US Dollar Index, another driver of gold prices (the dollar and gold usually move in opposite directions), fell 1% to 106.59. The surging dollar has pulled back from parity with the Euro and longtime highs against other major currencies despite the 9.1% inflation rate reported last week.

Barrick shares fell 3% in the past week and have declined 16% year to date. Earnings estimates are ticking down to follow gold prices. The shares have about 69% upside to our 27 price target. The price target is based on 7.5x estimated steady-state EBITDA and a modest premium to our estimate of $25/share of net asset value. BUY

Big Lots (BIG) – Big Lots is a discount general merchandise retailer based in Columbus, Ohio, with 1,431 stores across 47 states. Its stores offer an assortment of furniture, hard and soft home goods, apparel, electronics, food and consumables as well as seasonal merchandise. Our bullish case for Big Lots rests with its loyal and growing base of 22 million rewards members, its appeal to bargain-seeking customers, the relatively stable (albeit low) 5.5% cash operating profit margin, its positive free cash flow, debt-free balance sheet and low share valuation at 3.1x EV/EBITDA and 7.3x per-share earnings based on conservative January 2023 estimates.

Our thesis was deeply rattled by the company’s dismal first-quarter results. Offloading its bloated inventory will require sharp discounts, which will weigh on profits while the $271 million in new borrowing ramps up the risk. We are retaining our HOLD rating for now: investor expectations are sufficiently depressed to provide some downside cushion, while management should be able to extract itself from the worst of the inventory problem over the next few quarters. Nevertheless, the Big Lots investment is now high risk due to the new debt balance, the lost value from the inventory glut and the potential for a dividend cut.

There was no significant company-specific news in the past week.

Big Lots shares slipped 1% after a sharp jump a week ago. The shares have 53% upside to our recently reduced 35 price target. We would consider the dividend to be unsustainable and caution that investors should not count on any dividends from Big Lots. HOLD

Citigroup (C) – Citi is one of the world’s largest banks, with over $2.4 trillion in assets. The bank’s weak compliance and risk-management culture led to Citi’s disastrous and humiliating experience in the 2009 global financial crisis, which required an enormous government bailout. The successor CEO, Michael Corbat, navigated the bank through the post-crisis period to a position of reasonable stability. Unfinished, though, is the project to restore Citi to a highly profitable banking company, which is the task of new CEO Jane Fraser.

Citigroup reported encouraging second-quarter results. Revenues rose 11% and were about 7% above the consensus estimate. Earnings of $2.30/share fell 19% and were about 39% above the consensus estimate. The company maintained its full-year revenue and expense guidance. Overall, a good report, particularly compared to the dour investor sentiment.

Revenues were boosted by 33% growth in Trade & Treasury Solutions, a crown jewel of the bank which represents 15% of total revenues. Fixed income trading revenues (about 20% of total revenues) jumped 31% as the bank took advantage of investor uncertainty over the direction of inflation and interest rates. Credit card revenues rose 10% due to higher interest rates on higher balances. As expected, investment banking revenues fell sharply (-46%) as deal volumes shrank.

Total loans fell 2% from a year ago while deposits rose 1%. Citi’s loan/deposit ratio, a simple metric that evaluates the bank’s capacity to make loans, is at about 50%, suggesting that the bank could readily fund faster loan growth. The net interest margin expanded to 2.24%, indicating a wider level of profits on its lending compared to the 1.97% margin a year ago.

Credit quality remains sturdy as credit losses fell 36% from a year ago. The bank’s CET1 capital level rose to 11.9% from 11.8% a year ago despite sizeable dividends and share repurchases. This capital is supported by loan loss reserves that are a generous 2.4% of funded loans.

Citi shares trade at 64% of tangible book value. This immense discount, which assumes a dim future for Citi, appears to be misplaced.

This past week, the spread between the 90-day T-bill and the 10-year Treasury note, which approximates the drivers behind Citi’s net interest margin, narrowed by 43 basis points to 0.53%. There are 100 basis points in one percent. Short-term rates jumped this past week on conviction that the Fed will continue to ratchet up interest rates to fight high inflation. Long-term rates ticked up modestly.

A recession would likely increase Citi’s credit losses, a flatter yield curve would weigh on its net interest margin, and weaker capital markets would mean fewer investment banking revenues.

Citi shares jumped 11% following the encouraging earnings report and about 66% upside to our 85 price target. Citigroup investors enjoy a 4.0% dividend yield and perhaps another 3% or more in annual accretion from the bank’s share repurchase program once it reaches its new target capital ratio and if a slowing/stalling economy doesn’t meaningfully increase its credit costs. BUY

Molson Coors Beverage Company (TAP) is one of the world’s largest beverage companies, producing the highly recognized Coors, Molson, Miller and Blue Moon brands as well as numerous local, craft and specialty beers. About two-thirds of its revenues come from the United States, where it holds a 24% market share. Investors worry about Molson Coors’ lack of revenue growth due to its relatively limited offerings of fast-growing hard seltzers and other trendier beverages. Our thesis for this company is straight-forward – a reasonably stable company whose shares sell at an overly-discounted price. Its revenues are resilient, it produces generous cash flow and is reducing its debt. A new CEO is helping improve its operating efficiency and expand carefully into more growthier products. The company recently reinstated its dividend.

There was no significant company-specific news in the past week.

TAP shares rose 2% in the past week and have about 18% upside to our 69 price target. The stock remains cheap, particularly on an EV/EBITDA basis, or enterprise value/cash operating profits, where it trades at 9.5x estimated 2022 results, still among the lowest valuations in the consumer staples group and below other brewing companies. The 2.6% dividend yield only adds to the appeal.

Molson Coors was featured as the Cabot Stock of the Week this week. BUY

Organon & Company (OGN) was recently spun off from Merck. It specializes in patented women’s healthcare products and biosimilars, and also has a portfolio of mostly off-patent treatments. Organon will produce better internal growth with some boost through smart yet modest-sized acquisitions. It may eventually divest its Established Brands segment. The management and board appear capable, the company produces robust free cash flow, has modestly elevated debt and will pay a reasonable dividend. Investors have ignored the company, but we believe that Organon will produce at least stable and large free cash flows with a reasonable potential for growth. At our initial recommendation, the stock traded at a highly attractive 4x earnings.

There was no significant company-specific news in the past week.

OGN shares fell 3% in the past week and have about 45% upside to our 46 price target (using the same target as the Cabot Turnaround Letter). The shares continue to trade at a remarkably low valuation while offering an attractive 3.5% dividend yield. BUY

Sensata Technologies (ST) is a $3.8 billion (revenues) producer of nearly 47,000 highly-engineered sensors used by automotive (60% of revenues), heavy vehicle, industrial and aerospace customers. About two-thirds of its revenues are generated outside of the United States, with China producing about 21%. Investors undervalue Sensata’s durable franchise. Its sensors are typically critical components that generally produce high profit margins. As the sensors’ reliability is vital to safely and performance, customers are reluctant to switch to another supplier that may have lower prices but also lower or unproven quality. Sensata has an arguably under-leveraged balance sheet and generates healthy free cash flow. The relatively new CEO will likely continue to expand the company’s growth potential through acquisitions. Electric vehicles are an opportunity as they expand Sensata’s reachable market.

There was no significant company-specific news in the past week.

ST shares rose 5% in the past week and have about 77% upside to our 75 price target. Our price target looks optimistic in light of the broad market sell-off, but we will keep it for now, even as it may take longer for the shares to reach it. BUY

Disclosure:The chief analyst of the Cabot Undervalued Stocks Advisor personally holds shares of every recommended security, except for “New Buy” recommendations. The chief analyst may purchase or sell recommended securities but not before the fourth day after any changes in recommendation ratings has been emailed to subscribers. “New Buy” recommendations will be purchased by the chief analyst as soon as practical following the fourth day after the newsletter issue has been emailed to subscribers.

Growth/Income Portfolio
Stock (Symbol)Date AddedPrice Added7/19/22Capital Gain/LossCurrent Dividend YieldPrice TargetRating
Cisco Systems (CSCO)11-18-2041.3244.036.6%3.5%66.00Buy
Coca-Cola (KO)11-11-2053.5862.5316.7%2.7%69.00Hold
Dow Inc (DOW) *04-01-1953.5052.45-2.0%5.3%78.00Buy
Merck (MRK)12-9-2083.4792.3610.7%3.0%99.00Hold
Buy Low Opportunities Portfolio
Stock (Symbol)Date AddedPrice Added7/19/22Capital Gain/LossCurrent Dividend YieldPrice TargetRating
Allison Transmission Hldgs (ALSN)02-22-2239.9938.58-3.5%2.2%48.00Buy
Arcos Dorados (ARCO)04-28-215.416.6522.9%2.4%8.50Buy
Aviva (AVVIY)03-03-2110.759.49-11.7%5.9%14.00Buy
Barrick Gold (GOLD)03-17-2121.1316.03-24.1%2.5%27.00Buy
BigLots (BIG)04-12-2235.2422.54-36.0%5.3%35.00Hold
Citigroup (C)11-23-2168.1052.13-23.5%3.9%85.00Buy
Molson Coors (TAP)08-05-2036.5358.5760.3%2.6%69.00Buy
Organon (OGN)06-07-2131.4231.570.5%3.5%46.00Buy
Sensata Technologies (ST)02-17-2158.5742.72-27.1%1.0%75.00Buy

*Note: DOW price is based on April 1, 2019 closing price following spin-off from DWDP.

Buy – This stock is worth buying.
Strong Buy – This stock offers an unusually favorable risk/reward trade-off, often one that has been rated as a Buy yet the market has sold aggressively for temporary reasons. We recommend adding to existing positions.
Hold – The shares are worth keeping but the risk/return trade-off is not favorable enough for more buying nor unfavorable enough to warrant selling.
Sell – This stock is approaching or has reached our price target, its value has become permanently impaired or changes in its risk or other traits warrant a sale.

Note for stock table: For stocks rated Sell, the current price is the sell date price.

CUSA Valuation and Earnings
Growth/Income Portfolio
Current 2022
EPS Estimate
Current 2023
EPS Estimate
Change in
2022 Estimate
Change in
2023 Estimate
P/E 2022P/E 2023
CSCO 43.70 3.36 3.540.0%-0.6% 13.0 12.3
KO 62.34 2.47 2.640.0%-0.4% 25.2 23.6
DOW 52.42 8.01 7.14-0.2%-1.0% 6.5 7.3
MRK 92.72 7.37 7.430.0%0.3% 12.6 12.5
Buy Low Opportunities Portfolio
Current 2022
EPS Estimate
Current 2023
EPS Estimate
Change in
2022 Estimate
Change in
2023 Estimate
P/E 2022P/E 2023
ALSN 38.70 6.24 7.050.0%0.0% 6.2 5.5
ARCO 6.70 0.51 0.526.3%6.1% 13.1 12.9
AVVIY 9.48 1.03 1.30-3.6%-1.0% 9.2 7.3
GOLD 16.00 1.07 1.12-4.1%-4.6% 14.9 14.2
BIG 22.86 (2.43) 2.260.0%0.0% (9.4) 10.1
C 51.26 7.36 7.099.2%4.1% 7.0 7.2
TAP 58.53 3.93 4.270.0%0.0% 14.9 13.7
OGN 31.74 5.26 5.64-0.4%-0.7% 6.0 5.6
ST 42.31 3.82 4.40-0.3%-0.2% 11.1 9.6

Current price is yesterday’s mid-day price.
CSCO: Estimates are for fiscal years ending in July.